Are you Dr. Shah?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Amishi Shah, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Arizona. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
University of Pennsylvania Health SystemResidency, Internal Medicine, 2010 - 2013
Baylor College of MedicineClass of 2010
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
TX State Medical License 2016 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer Start of enrollment: 2019 Apr 11
Publications & Presentations
PubMed
- Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma.Tian Zhang, Alan Tan, Amishi Y Shah, Gopa Iyer, Valerie Morris
The Oncologist. 2024-12-06 - Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer.Patrick Carriere, Omar Alhalabi, Jianjun Gao, Osama Mohamad, Matthew T Campbell
Clinical and Translational Radiation Oncology. 2024-11-01 - 1 citationsLenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNO...Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone
European Urology. 2024-11-01
Authored Content
- Cabozantinib for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Retrospective AnalysisNovember 2018
Press Mentions
MDACC 2018: Neoadjuvant Strategies for Upper Tract Urothelial CarcinomaNovember 11th, 2018
